Advertisement
Screener

Bicara Therapeutics Inc. (BCAX) Graph

BCAX Revenue Flow

A current filed revenue breakdown could not be established from the retained filing evidence.

  • 2026-06-30: Research and development (m); Operating expenses $59.95M; Income tax $61.00K; Net income -$55.44M.
  • 2026-03-31: Research and development (m); Operating expenses $60.24M; Income tax $52.00K; Net income -$56.21M.
  • 2025-12-31: Research and development (m); Operating expenses $41.12M*; Income tax $53.00K*; Net income -$37.39M*.
  • 2025-09-30: Research and development $33.00M; Operating expenses $40.68M; Income tax $40.00K; Net income -$36.33M.

Finer product or service dollar figures and nonoverlapping groupings are shown only where supported by the retained filing evidence. Growth percentages are never converted to revenue dollars.

Historical revenue and expense breakdown

Revenue and expense 3 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$59.95M$61.00K-$55.44M
2026-03-31(m)$60.24M$52.00K-$56.21M
2025-12-31(m)$41.12M*$53.00K*-$37.39M*
2025-09-30$33.00M$40.68M$40.00K-$36.33M
2025-06-30$24.80M$32.02M$52.00K-$27.39M
2025-03-31$34.30M$41.79M$72.00K-$36.85M
2024-09-30$15.90M$20.63M$0.00-$17.48M
2024-06-30$15.80M$19.75M$0.00-$17.05M
2024-03-31$12.00M$15.37M$1.00K-$12.51M
2023-09-30$6.90M$9.53M$0.00-$22.84M
2023-06-30(m)(m)(m)-$9.29M
2023-03-31(m)(m)(m)-$7.41M

Revenue and expense 6 month

Period endResearch and developmentOperating expensesIncome taxNet income
2026-06-30(m)$120.19M$115.00K-$111.65M
2025-06-30$59.10M$73.81M$124.00K-$64.23M
2024-06-30$27.90M$35.12M$1.00K-$29.56M

Revenue and expense 9 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-09-30$92.10M$114.48M$164.00K-$100.56M
2024-09-30$43.70M$55.75M$1.00K-$47.04M
2023-09-30$20.10M$26.20M$0.00-$39.55M

Revenue and expense 12 month

Period endResearch and developmentOperating expensesIncome taxNet income
2025-12-31(m)$155.60M$217.00K-$137.95M
2024-12-31$63.60M$82.39M$187.00K-$68.00M
2023-12-31$30.60M$39.89M$5.00K-$51.98M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Tyra Biosciences, Inc. (TYRA)United States$1.337B-12.83
First Tracks Biotherapeutics, Inc. (TRAX)United States$1.280B
Kardigan, Inc. (KARD)United States$1.346B
Avalyn Pharma Inc. (AVLN)United States$1.267B
Oric Pharmaceuticals, Inc. (ORIC)United States$1.367B-8.00
Damora Therapeutics, Inc. (DMRA)$1.250B-6.10
HARROW, INC. (HROW)United States$1.240B-42.77
OPKO HEALTH, INC. (OPK)United States$1.220B-15.59
LB PHARMACEUTICALS INC (LBRX)United States$1.220B-10.87
Jaguar Health, Inc. (JAGX)United States$1.184B